{"id":"NCT01010633","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2010-06","completion":"2010-08","firstPosted":"2009-11-10","resultsPosted":"2012-01-09","lastUpdate":"2012-01-09"},"enrollment":406,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Inflammation","Pain"],"interventions":[{"type":"DRUG","name":"Vehicle of Loteprednol Etabonate","otherNames":[]},{"type":"DRUG","name":"Loteprednol Etabonate","otherNames":[]}],"arms":[{"label":"Loteprednol Etabonate","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This study is being conducted to compare the safety and efficacy of loteprednol etabonate compared to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.","primaryOutcome":{"measure":"Resolution of Anterior Chamber Cells (ACC).","timeFrame":"Visit 5 (Postoperative day 8)","effectByArm":[{"arm":"Loteprednol","deltaMin":62,"sd":null},{"arm":"Vehicle","deltaMin":33,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["24136301"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":203},"commonTop":[]}}